Pharmaceutical composition for treating cataract and manufacture thereof

Abstract

This invention discloses a pharmaceutical composition for treating cataracts and a method for preparing the same, comprising: a plurality of nanocells, further comprising: a block copolymer composed of hydrophobic and hydrophilic segments, wherein the block copolymer is a copolymer of formula (I); and an amphiphilic drug, which is encapsulated in the nanocells.

Claims

1. A pharmaceutical composition for treating cataracts, comprising: a plurality of nanocells, further comprising: a block copolymer consisting of hydrophobic and hydrophilic segments, wherein the block copolymer is as shown in Formula (I): Formula (I); and an amphiphilic drug coated in the nanocells, wherein m is an integer from 15 to 250, n is an integer from 5 to 100, and o is an integer from 5 to 200.

2. The pharmaceutical composition for treating cataracts as described in claim 1, wherein the pharmaceutical composition is an eye drop formulation or an oral formulation.

3. The pharmaceutical composition for treating cataracts as described in claim 1, wherein the amphiphilic drug is a sodium-glucose cotransporter 2 inhibitor (SGLT2).

4. The pharmaceutical composition for treating cataracts as described in claim 1, wherein the cataracts are diabetes-related cataracts.

5. The pharmaceutical composition for treating cataracts as described in claim 1, wherein the pharmaceutical composition is further used in combination with a biological reducing agent.

6. A method for preparing a pharmaceutical composition, comprising: synthesizing a polymer copolymer by using polyethylene glycol (PEG), L-lactide, and a bond-functionalized lactic acid monomer as raw materials, and subjecting them to an olefin metathesis reaction with a free radical initiator to obtain a copolymer of formula (I) as described in claim 1; synthesizing at least one nanocell by mixing the copolymer of formula (I), a crosslinking agent, an inorganic salt compound, an antioxidant, and deionized water to perform emulsification, thereby self-assembling the nanocells; and synthesizing at least one pharmaceutical composition by mixing the copolymer of formula (I) with an amphiphilic drug and dissolving it into a mixed solution, and then mixing the mixed solution with the crosslinking agent, the inorganic salt compound, the antioxidant, and the deionized water to perform emulsification, thereby self-assembling the pharmaceutical composition.

7. A method for preparing the pharmaceutical composition as claimed in claim 7, wherein the amphiphilic drug is a sodium-glucose cotransporter 2 inhibitor (SGLT2).

8. A method for preparing a pharmaceutical composition as described in claim 7, wherein the crosslinking agent is an azide compound.

9. A method for preparing a pharmaceutical composition as described in claim 7, wherein the pharmaceutical composition is an eye drop dosage form or an oral dosage form.

10. The method for preparing the pharmaceutical composition as claimed in claim 7, wherein in the step of synthesizing the polymer copolymer, the degree of polymerization of the copolymer of formula (I) is controlled by adjusting the proportions of polyethylene glycol, L-lactide, bond-functionalized lactic acid monomer and the free radical initiator.

Images